Cardiovascular disorder

disease

On this page

Also known as cardiovascular diseasecardiovascular disease (CVD)cardiovascular system diseasecardiovascular system disease or disordercirculatory system diseasedisease of cardiovascular systemdisease or disorder of cardiovascular systemdisorder of cardiovascular system

Summary

Cardiovascular disorder (MONDO:0004995) is a disease (an umbrella term covering 6 Mondo subtypes) with 19 cohort genes (564 GWAS associations across 97 studies) and 4,079 clinical trials. Top therapeutic interventions include enalapril, rosuvastatin, and clopidogrel.

At a glance

Umbrella term: 6 Mondo subtypes
Cohort genes: 19
GWAS associations: 564
ClinVar variants: 1
Clinical trials: 4,079

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cardiovascular disorder
Mondo ID	MONDO:0004995
EFO	EFO:0000319
MeSH	D002318
DOID	DOID:1287
ICD-10-CM	I00-I99
ICD-11	424293435, 426429380
NCIT	C2931
SNOMED CT	49601007
UMLS	C0007222
MedGen	2848
Anatomy (UBERON)	UBERON:0004535
Is cancer (heuristic)	no

Also known as: cardiovascular disease · cardiovascular disease (CVD) · cardiovascular disorder · cardiovascular system disease · cardiovascular system disease or disorder · circulatory system disease · disease of cardiovascular system · disease or disorder of cardiovascular system · disorder of cardiovascular system

Data availability: 1 ClinVar variant · 564 GWAS associations (97 studies).

Disease family

An umbrella term covering 6 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder

Subtypes (6): autoimmune disorder of cardiovascular system, heart disorder, vascular disorder, autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome, congenital anomaly of cardiovascular system, cardiovascular neoplasm

Genetics & variants

GWAS landscape

564 GWAS associations across 97 studies. Top hits map to 19 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele
rs4007642	3e-84	CDKN2B-AS1	?
rs13125101	1e-80	PRDM8 - FGF5	?
rs74617384	5e-74	LPA	?
rs7412	3e-63	APOE	?
rs3918226	2e-49	NOS3	?
rs72831343	1e-47	CABCOCO1, LINC02625	?
rs140570886	1e-47	LPA	?
rs2290400	7e-44	GSDMB	?
rs2305479	7e-44	GSDMB	?
rs7216389	2e-43	GSDMB	?
rs7219923	2e-43	GSDMB	?
rs7224129	2e-43	GSDMB	?
rs9303281	2e-43	GSDMB	?
rs12978472	3e-43	INSR	?
rs1008723	5e-43	GSDMB	?
rs869402	7e-42	GSDMB	?
rs167479	9e-42	RGL3	?
rs9303277	1e-41	IKZF3	?
rs9901146	2e-41	ZPBP2 - GSDMB	?
rs12950743	2e-41	ZPBP2 - GSDMB	?
rs8067378	3e-41	ZPBP2 - GSDMB	?
rs4795405	1e-40	LRRC3C	?
rs604723	8e-40	ARHGAP42	?
rs9303280	2e-39	GSDMB	?
rs3816470	3e-39	IKZF3	?
rs10059884	6e-39	NPR3 - LINC02120	?
rs12603332	1e-38	ORMDL3	?
rs7359623	3e-38	ZPBP2 - GSDMB	?
rs1275988	1e-37	RPL37P11 - KCNK3	?
rs7267618	2e-37	ZNF831	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90044348	Jiang L	2021	320,315	134,988	A generalized linear mixed model association tool for biobank-scale data.
GCST90038595	Donertas HM	2021	177,923	306,675	Common genetic associations between age-related diseases.
GCST90446535	Guo Y	2023	44,238	414,900	Genome-Wide Assessment of Shared Genetic Architecture Between Rheumatoid Arthritis and Cardiovascular Diseases.
GCST90475217	Verma A	2024	28,091	287,577	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90081364	Backman JD	2021	22,886	360,766	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90085350	Backman JD	2021	22,886	360,766	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90473623	UK Biobank Whole-Genome Sequencing Consortium	2025	22,106	436,334	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90103427	Zhou Y	2022	19,954	107,715	Shared Genetic Architecture and Causal Relationship Between Asthma and Cardiovascular Diseases: A Large-Scale Cross-Trait Analysis.
GCST90475218	Verma A	2024	18,522	297,146	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436187	Zhou W	2018	16,544	387,905	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	7
Tier 2: splice/UTR	3
Tier 3: regulatory	1
Tier 4: intronic/intergenic	39

MAF distribution

Bucket	Variants
common (>=0.05)	50
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	27
intergenic_variant	12
missense_variant	7
3_prime_UTR_variant	2
5_prime_UTR_variant	1
regulatory_region_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs4007642	9	22093300	A>C,T	0.05	intron_variant	CDKN2B-AS1	3e-84	Tier 4: intronic/intergenic
rs13125101	4	80253438	G>A	0.05	intergenic_variant	PRDM8 - FGF5	1e-80	Tier 4: intronic/intergenic
rs74617384	6	160576086	A>C,G,T	0.05	intron_variant	LPA	5e-74	Tier 4: intronic/intergenic
rs7412	19	44908822	C>T	0.05	missense_variant	APOE	3e-63	Tier 1: coding
rs3918226	7	150993088	C>T	0.05	intron_variant	NOS3	2e-49	Tier 4: intronic/intergenic
rs72831343	10	61755923	T>G	0.05	intron_variant	CABCOCO1, LINC02625	1e-47	Tier 4: intronic/intergenic
rs140570886	6	160591981	T>C	0.05	intron_variant	LPA	1e-47	Tier 4: intronic/intergenic
rs2290400	17	39909987	T>A,C,G	0.05	intron_variant	GSDMB	7e-44	Tier 4: intronic/intergenic
rs2305479	17	39905964	C>A,T	0.05	missense_variant	GSDMB	7e-44	Tier 1: coding
rs7216389	17	39913696	C>T	0.05	intron_variant	GSDMB	2e-43	Tier 4: intronic/intergenic
rs7219923	17	39918265	C>A,T	0.05	intron_variant	GSDMB	2e-43	Tier 4: intronic/intergenic
rs7224129	17	39919173	G>A	0.05	intergenic_variant	GSDMB	2e-43	Tier 4: intronic/intergenic
rs9303281	17	39917793	G>A	0.05	intron_variant	GSDMB	2e-43	Tier 4: intronic/intergenic
rs12978472	19	7257979	C>A,G,T	0.05	intron_variant	INSR	3e-43	Tier 4: intronic/intergenic
rs1008723	17	39910014	G>C,T	0.05	intron_variant	GSDMB	5e-43	Tier 4: intronic/intergenic
rs869402	17	39911790	T>A,C,G	0.05	intron_variant	GSDMB	7e-42	Tier 4: intronic/intergenic
rs167479	19	11416089	T>A,C,G	0.05	missense_variant	RGL3	9e-42	Tier 1: coding
rs9303277	17	39820216	C>G,T	0.05	intron_variant	IKZF3	1e-41	Tier 4: intronic/intergenic
rs9901146	17	39887090	G>A	0.05	intergenic_variant	ZPBP2 - GSDMB	2e-41	Tier 4: intronic/intergenic
rs12950743	17	39892980	T>C	0.05	intergenic_variant	ZPBP2 - GSDMB	2e-41	Tier 4: intronic/intergenic
rs8067378	17	39895095	A>C,G	0.05	intergenic_variant	ZPBP2 - GSDMB	3e-41	Tier 4: intronic/intergenic
rs4795405	17	39932164	T>A,C,G	0.05	intron_variant	LRRC3C	1e-40	Tier 4: intronic/intergenic
rs604723	11	100739815	T>C	0.05	intron_variant	ARHGAP42	8e-40	Tier 4: intronic/intergenic
rs9303280	17	39917778	T>A,C	0.05	intron_variant	GSDMB	2e-39	Tier 4: intronic/intergenic
rs3816470	17	39829548	A>C,G	0.05	intron_variant	IKZF3	3e-39	Tier 4: intronic/intergenic
rs10059884	5	32832368	C>A,G,T	0.05	intergenic_variant	NPR3 - LINC02120	6e-39	Tier 4: intronic/intergenic
rs12603332	17	39926554	T>C	0.05	5_prime_UTR_variant	ORMDL3	1e-38	Tier 2: splice/UTR
rs7359623	17	39893336	C>T	0.05	intergenic_variant	ZPBP2 - GSDMB	3e-38	Tier 4: intronic/intergenic
rs1275988	2	26691496	C>T	0.05	intron_variant	RPL37P11 - KCNK3	1e-37	Tier 4: intronic/intergenic
rs7267618	20	59131469	T>G	0.05	intron_variant	ZNF831	2e-37	Tier 4: intronic/intergenic

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
3068675	NM_001458.5(FLNC):c.4467del (p.Glu1489fs)	FLNC	Likely pathogenic	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 14 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SORL1	Orphanet:1020	Early-onset autosomal dominant Alzheimer disease
STX16	Orphanet:94089	Pseudohypoparathyroidism type 1B
PRDM16	Orphanet:154	Familial isolated dilated cardiomyopathy
PRDM16	Orphanet:1606	1p36 deletion syndrome
PRDM16	Orphanet:54260	Left ventricular noncompaction
APOA5	Orphanet:530849	Familial apolipoprotein A5 deficiency
HHAT	Orphanet:1422	Chondrodysplasia-difference of sex development syndrome
FLNC	Orphanet:171445	Muscle filaminopathy
FLNC	Orphanet:63273	FLNC-related handgrip and calf weakness-distal myopathy
FLNC	Orphanet:75249	Familial isolated restrictive cardiomyopathy
GK	Orphanet:284411	Glycerol kinase deficiency, juvenile form
GK	Orphanet:284414	Glycerol kinase deficiency, adult form
GLUL	Orphanet:71278	Congenital brain dysgenesis due to glutamine synthetase deficiency
IL1RAPL1	Orphanet:777	X-linked non-syndromic intellectual disability

Cohort genes → proteins

19 cohort genes, 19 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	18
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SORL1	HGNC:11185	ENSG00000137642	Q92673	Sortilin-related receptor	gwas
STX16	HGNC:11431	ENSG00000124222	O14662	Syntaxin-16	gwas
MEPE	HGNC:13361	ENSG00000152595	Q9NQ76	Matrix extracellular phosphoglycoprotein	gwas
PRDM16	HGNC:14000	ENSG00000142611	Q9HAZ2	Histone-lysine N-methyltransferase PRDM16	gwas
AGAP1	HGNC:16922	ENSG00000157985	Q9UPQ3	Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 1	gwas
APOA5	HGNC:17288	ENSG00000110243	Q6Q788	Apolipoprotein A-V	gwas
ZNF648	HGNC:18190	ENSG00000179930	Q5T619	Zinc finger protein 648	gwas
HHAT	HGNC:18270	ENSG00000054392	Q5VTY9	Protein-cysteine N-palmitoyltransferase HHAT	gwas
SAYSD1	HGNC:21025	ENSG00000112167	Q9NPB0	SAYSvFN domain-containing protein 1	gwas
APCDD1L	HGNC:26892	ENSG00000198768	Q8NCL9	Protein APCDD1-like	gwas
BUD13	HGNC:28199	ENSG00000137656	Q9BRD0	BUD13 homolog	gwas
BLID	HGNC:33495	ENSG00000259571	Q8IZY5	BH3-like motif-containing cell death inducer	gwas
FLNC	HGNC:3756	ENSG00000128591	Q14315	Filamin-C	clinvar
GK	HGNC:4289	ENSG00000198814	P32189	Glycerol kinase	gwas
GLUL	HGNC:4341	ENSG00000135821	P15104	Glutamine synthetase	gwas
CADM1	HGNC:5951	ENSG00000182985	Q9BY67	Cell adhesion molecule 1	gwas
IL1RAPL1	HGNC:5996	ENSG00000169306	Q9NZN1	Interleukin-1 receptor accessory protein-like 1	gwas
IRX4	HGNC:6129	ENSG00000113430	P78413	Iroquois-class homeodomain protein IRX-4	gwas
BACE1	HGNC:933	ENSG00000186318	P56817	Beta-secretase 1	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SORL1	Sortilin-related receptor	Sorting receptor that directs several proteins to their correct location within the cell.
STX16	Syntaxin-16	SNARE involved in vesicular transport from the late endosomes to the trans-Golgi network.
MEPE	Matrix extracellular phosphoglycoprotein	Promotes renal phosphate excretion and inhibits intestinal phosphate absorption.
PRDM16	Histone-lysine N-methyltransferase PRDM16	Transcription regulator that acts both as a histone methyltransferase or chromatin adapter, depending on the context.
AGAP1	Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 1	GTPase-activating protein for ARF1 and, to a lesser extent, ARF5.
APOA5	Apolipoprotein A-V	Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL.
ZNF648	Zinc finger protein 648	May be involved in transcriptional regulation.
HHAT	Protein-cysteine N-palmitoyltransferase HHAT	Palmitoyl acyltransferase that catalyzes N-terminal palmitoylation of SHH; which is required for SHH signaling.
SAYSD1	SAYSvFN domain-containing protein 1	Ufmylation ‘reader’ component of a translocation-associated quality control pathway, a mechanism that takes place when a ribosome has stalled during translation, and which is required to degrade clogged substrates.
BUD13	BUD13 homolog	Involved in pre-mRNA splicing as component of the activated spliceosome.
BLID	BH3-like motif-containing cell death inducer	Functions as a proapoptotic molecule through the caspase-dependent mitochondrial pathway of cell death.
FLNC	Filamin-C	Muscle-specific filamin, which plays a central role in sarcomere assembly and organization.
GK	Glycerol kinase	Kinase that plays a key role in glycerol metabolism, catalyzing its phosphorylation to produce sn-glycerol 3-phosphate.
GLUL	Glutamine synthetase	Glutamine synthetase that catalyzes the ATP-dependent conversion of glutamate and ammonia to glutamine.
CADM1	Cell adhesion molecule 1	Mediates homophilic cell-cell adhesion in a Ca(2+)-independent manner.
IL1RAPL1	Interleukin-1 receptor accessory protein-like 1	May regulate secretion and presynaptic differentiation through inhibition of the activity of N-type voltage-gated calcium channel.
IRX4	Iroquois-class homeodomain protein IRX-4	Likely to be an important mediator of ventricular differentiation during cardiac development.
BACE1	Beta-secretase 1	Responsible for the proteolytic processing of the amyloid precursor protein (APP).

Protein-family classification

Druggable: 7 · Difficult: 4 · Unknown: 8 · Druggable fraction: 0.37

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Antibody/Immunoglobulin	4	6.2×	0.025
Protease	1	1.9×	0.880
Kinase	1	1.5×	0.880
Transcription factor	3	1.3×	0.880
Scaffold/PPI	1	0.9×	0.924
Other/Unknown	8	0.8×	0.924
Enzyme (other)	1	0.6×	0.924

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SORL1	Antibody/Immunoglobulin	yes		LDLR_classB_rpt, LDrepeatLR_classA_rpt, FN3_dom
STX16	Other/Unknown	no		T_SNARE_dom, Syntaxin/epimorphin_CS, SNARE
MEPE	Other/Unknown	no		MEPE
PRDM16	Transcription factor	no	2.1.1.367	SET_dom, Znf_C2H2_type, Znf_C2H2_sf
AGAP1	Scaffold/PPI	no		ArfGAP_dom, Small_GTPase, PH_domain
APOA5	Other/Unknown	no		ApoA_E, Apolipoprotein_A1/A4/E
ZNF648	Transcription factor	no		Znf_C2H2_type, Znf_C2H2_sf
HHAT	Other/Unknown	no		MBOAT_fam, MB_O-acyltransferase
SAYSD1	Other/Unknown	no		SAYSvFN_dom, SAYSD1
APCDD1L	Other/Unknown	no		APCDD1_dom, APCDD1
BUD13	Other/Unknown	no		Bud13, CWC26_splicing_factor
BLID	Other/Unknown	no
FLNC	Antibody/Immunoglobulin	yes		Filamin/ABP280_rpt, Actinin_actin-bd_CS, CH_dom
GK	Kinase	yes	2.7.1.30	Carb_kinase_FGGY, Glycerol_kin, Carb_kinase_FGGY_CS
GLUL	Enzyme (other)	yes	6.3.1.2	Gln_synth_cat_dom, Gln_synt_N, Gln_synth/guanido_kin_cat_dom
CADM1	Antibody/Immunoglobulin	yes		Neurexin-like, Ig_sub2, Ig_sub
IL1RAPL1	Antibody/Immunoglobulin	yes		TIR_dom, Ig_sub2, Ig_sub
IRX4	Transcription factor	no		HD, Iroquois_homeo, KN_HD
BACE1	Protease	yes	3.4.23.46	Aspartic_peptidase_A1, Aspartic_peptidase_AS, BACE

Expression context

Cohort genes with no expression data: 0.

16 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	1
broad (>20)	18
unknown	0

Top tissues across cohort

Tissue	Cohort genes
paraflocculus	3
corpus callosum	3
frontal pole	2
sural nerve	2
liver	2
male germ line stem cell (sensu Vertebrata) in testis	2
primordial germ cell in gonad	2
adrenal tissue	2
endothelial cell	2
middle frontal gyrus	1
right uterine tube	1
periodontal ligament	1
tibia	1
trabecular bone tissue	1
ascending aorta	1
pigmented layer of retina	1
cortical plate	1
right lobe of liver	1
skeletal muscle tissue of rectus abdominis	1
olfactory segment of nasal mucosa	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SORL1	293	ubiquitous	marker	frontal pole, paraflocculus, middle frontal gyrus
STX16	300	broad	marker	right uterine tube, sural nerve, corpus callosum
MEPE	52	tissue_specific	marker	tibia, periodontal ligament, trabecular bone tissue
PRDM16	202	broad	marker	sural nerve, pigmented layer of retina, ascending aorta
AGAP1	287	ubiquitous	marker	frontal pole, cortical plate, paraflocculus
APOA5	45	tissue_specific	yes	right lobe of liver, liver, skeletal muscle tissue of rectus abdominis
ZNF648	19		marker	male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad, liver
HHAT	137	ubiquitous	yes	male germ line stem cell (sensu Vertebrata) in testis, olfactory segment of nasal mucosa, primordial germ cell in gonad
SAYSD1	256	ubiquitous	marker	left testis, right testis, sperm
APCDD1L	125	broad	marker	kidney epithelium, vena cava, stromal cell of endometrium
BUD13	246	ubiquitous	marker	secondary oocyte, oocyte, tendon of biceps brachii
BLID	39		yes	cartilage tissue, calcaneal tendon, corpus callosum
FLNC	255	ubiquitous	marker	gastrocnemius, hindlimb stylopod muscle, tibialis anterior
GK	243	ubiquitous	marker	jejunal mucosa, adrenal tissue, duodenum
GLUL	309	ubiquitous	marker	endothelial cell, medial globus pallidus, globus pallidus
CADM1	294	ubiquitous	marker	paraflocculus, pons, adrenal tissue
IL1RAPL1	115	broad	marker	buccal mucosa cell, endothelial cell, corpus callosum
IRX4	93	broad	marker	skin of abdomen, apex of heart, cervix squamous epithelium
BACE1	278	ubiquitous	marker	inferior vagus X ganglion, body of pancreas, C1 segment of cervical spinal cord

Protein interactions among cohort

Intra-cohort edges: 2.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
GLUL	5,006
FLNC	3,174
BACE1	2,883
CADM1	2,700
PRDM16	2,633
SORL1	2,524
GK	2,358
BUD13	2,107
APOA5	1,919
STX16	1,793

Intra-cohort edges

A	B	Sources
APOA5	BUD13	string_interaction
BLID	SORL1	string_interaction

Structural data

PDB: 11 · AlphaFold-only: 8 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
BACE1	P56817	350
FLNC	Q14315	14
GLUL	P15104	12
BUD13	Q9BRD0	11
HHAT	Q5VTY9	10
SORL1	Q92673	7
IL1RAPL1	Q9NZN1	3
PRDM16	Q9HAZ2	2
AGAP1	Q9UPQ3	2
CADM1	Q9BY67	2
STX16	O14662	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
GK	P32189	92.01
APCDD1L	Q8NCL9	82.31
APOA5	Q6Q788	72.38
SAYSD1	Q9NPB0	66.34
ZNF648	Q5T619	61.00
IRX4	P78413	54.03
BLID	Q8IZY5	50.81
MEPE	Q9NQ76	43.45

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 44. Enrichment computed across 19 evidence-associated genes (13 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 13 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Interleukin-38 signaling	1	219.6×	0.060	IL1RAPL1
HHAT G278V doesn’t palmitoylate Hh-Np	1	175.7×	0.060	HHAT
Astrocytic Glutamate-Glutamine Uptake And Metabolism	1	146.4×	0.060	GLUL
Nectin/Necl trans heterodimerization	1	109.8×	0.060	CADM1
Amyloid fiber formation	2	15.8×	0.060	SORL1, BACE1
Post-translational protein phosphorylation	2	15.4×	0.060	MEPE, APOA5
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	2	13.3×	0.060	MEPE, APOA5
Chylomicron remodeling	1	87.8×	0.062	APOA5
Glutamate and glutamine metabolism	1	62.8×	0.070	GLUL
Cell-extracellular matrix interactions	1	51.7×	0.070	FLNC
Triglyceride biosynthesis	1	51.7×	0.070	GK
Metabolism of proteins	4	3.8×	0.070	SORL1, MEPE, APOA5, BACE1
Assembly of active LPL and LIPC lipase complexes	1	46.2×	0.071	APOA5
Receptor-type tyrosine-protein phosphatases	1	43.9×	0.071	IL1RAPL1
Plasma lipoprotein remodeling	1	36.6×	0.079	APOA5
Transcriptional regulation of brown and beige adipocyte differentiation by EBF2	1	29.3×	0.092	PRDM16
Interleukin-1 family signaling	1	20.9×	0.107	IL1RAPL1
Protein-protein interactions at synapses	1	20.4×	0.107	IL1RAPL1
Intra-Golgi traffic	1	20.0×	0.107	STX16
Adherens junctions interactions	1	19.1×	0.107	CADM1
Cell-cell junction organization	1	19.1×	0.107	CADM1
Plasma lipoprotein assembly, remodeling, and clearance	1	17.6×	0.110	APOA5
Retrograde transport at the Trans-Golgi-Network	1	16.9×	0.110	STX16
Hedgehog ligand biogenesis	1	16.3×	0.110	HHAT
Cell junction organization	1	14.4×	0.118	CADM1
PKMTs methylate histone lysines	1	12.4×	0.132	PRDM16
Regulation of lipid metabolism by PPARalpha	1	10.8×	0.142	APOA5
Cell-Cell communication	1	10.6×	0.142	CADM1
mRNA Splicing	1	8.4×	0.170	BUD13
Intra-Golgi and retrograde Golgi-to-ER traffic	1	8.1×	0.172	STX16

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 19 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
obsolete glutamine biosynthetic process	1	887.0×	0.027	GLUL
establishment of animal organ orientation	1	887.0×	0.027	IRX4
intracellular ammonium homeostasis	1	887.0×	0.027	GLUL
obsolete positive regulation of early endosome to recycling endosome transport	1	887.0×	0.027	SORL1
negative regulation of neurofibrillary tangle assembly	1	887.0×	0.027	SORL1
triglyceride metabolic process	2	46.7×	0.027	APOA5, GK
positive regulation of very-low-density lipoprotein particle remodeling	1	443.5×	0.028	APOA5
N-terminal peptidyl-L-cysteine N-palmitoylation	1	443.5×	0.028	HHAT
detection of stimulus	1	443.5×	0.028	CADM1
negative regulation of white fat cell differentiation	1	443.5×	0.028	PRDM16
positive regulation of glial cell-derived neurotrophic factor production	1	443.5×	0.028	SORL1
triglyceride-rich lipoprotein particle remodeling	1	295.6×	0.028	APOA5
susceptibility to natural killer cell mediated cytotoxicity	1	295.6×	0.028	CADM1
trans-synaptic signaling by trans-synaptic complex	1	295.6×	0.028	IL1RAPL1
beige fat cell differentiation	1	295.6×	0.028	PRDM16
regulation of protein localization to nucleolus	1	295.6×	0.028	GLUL
tolerance induction in gut-associated lymphoid tissue	1	221.7×	0.028	PRDM16
L-glutamate catabolic process	1	221.7×	0.028	GLUL
insulin receptor recycling	1	221.7×	0.028	SORL1
glycerol-3-phosphate biosynthetic process	1	221.7×	0.028	GK
signaling receptor ligand precursor processing	1	221.7×	0.028	BACE1
very-low-density lipoprotein particle clearance	1	177.4×	0.028	APOA5
swimming behavior	1	177.4×	0.028	BACE1
protein retention in Golgi apparatus	1	177.4×	0.028	SORL1
acylglycerol homeostasis	1	177.4×	0.028	APOA5
endosome to plasma membrane protein transport	1	177.4×	0.028	SORL1
positive regulation of ER to Golgi vesicle-mediated transport	1	177.4×	0.028	SORL1
negative regulation of amyloid precursor protein catabolic process	1	177.4×	0.028	SORL1
retrograde transport, endosome to Golgi	2	21.6×	0.028	SORL1, STX16
negative regulation of triglyceride catabolic process	1	147.8×	0.029	SORL1

Therapeutics

Drugs indicated for this disease

173 approved, 65 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Acebutolol	Approved (phase 4)
Acetyldigitoxin	Approved (phase 4)
Acipimox	Approved (phase 4)
Adenosine	Approved (phase 4)
Alipogene Tiparvovec	Approved (phase 4)
Alirocumab	Approved (phase 4)
Aliskiren	Approved (phase 4)
Alprostadil	Approved (phase 4)
Amiloride	Approved (phase 4)
Amlodipine	Approved (phase 4)
Angiotensin Ii	Approved (phase 4)
Arbutamine	Approved (phase 4)
Atenolol	Approved (phase 4)
Atorvastatin	Approved (phase 4)
Bempedoic Acid	Approved (phase 4)
Benazepril	Approved (phase 4)
Bendroflumethiazide	Approved (phase 4)
Benziodarone	Approved (phase 4)
Bepridil	Approved (phase 4)
Betaxolol	Approved (phase 4)
Bezafibrate	Approved (phase 4)
Bisoprolol	Approved (phase 4)
Buflomedil	Approved (phase 4)
Bumetanide	Approved (phase 4)
Camphor	Approved (phase 4)
Canrenone	Approved (phase 4)
Captopril	Approved (phase 4)
Carteolol	Approved (phase 4)
Carvedilol	Approved (phase 4)
Celiprolol	Approved (phase 4)
Cerivastatin	Approved (phase 4)
Chlorothiazide	Approved (phase 4)
Chlorthalidone	Approved (phase 4)
Cholestyramine	Approved (phase 4)
Cilazapril	Approved (phase 4)
Cinepazide	Approved (phase 4)
Ciprofibrate	Approved (phase 4)
Clevidipine	Approved (phase 4)
Clofibrate	Approved (phase 4)
Colesevelam	Approved (phase 4)
Colestipol Hydrochloride	Approved (phase 4)
Conivaptan	Approved (phase 4)
Cyclandelate	Approved (phase 4)
Cyclothiazide	Approved (phase 4)
Deslanoside	Approved (phase 4)
Dextrothyroxine	Approved (phase 4)
Digitoxin	Approved (phase 4)
Digoxin	Approved (phase 4)
Diltiazem	Approved (phase 4)
Diosmin	Approved (phase 4)
Dobutamine	Approved (phase 4)
Dopamine	Approved (phase 4)
Droxidopa	Approved (phase 4)
Enalapril	Approved (phase 4)
Enoximone	Approved (phase 4)
Ephedrine	Approved (phase 4)
Epinephrine	Approved (phase 4)
Eplerenone	Approved (phase 4)
Eprosartan	Approved (phase 4)
Esmolol	Approved (phase 4)
Ethacrynic Acid	Approved (phase 4)
Evinacumab	Approved (phase 4)
Evolocumab	Approved (phase 4)
Ezetimibe	Approved (phase 4)
Felodipine	Approved (phase 4)
Fenofibrate	Approved (phase 4)
Fenoldopam	Approved (phase 4)
Finerenone	Approved (phase 4)
Flosequinan	Approved (phase 4)
Fluvastatin	Approved (phase 4)
Fosinopril	Approved (phase 4)
Furosemide	Approved (phase 4)
Gemfibrozil	Approved (phase 4)
Hydrochlorothiazide	Approved (phase 4)
Hydroflumethiazide	Approved (phase 4)
Ibuprofen	Approved (phase 4)
Idecabtagene Vicleucel	Approved (phase 4)
Imidapril	Approved (phase 4)
Inamrinone	Approved (phase 4)
Indapamide	Approved (phase 4)
Indomethacin	Approved (phase 4)
Irbesartan	Approved (phase 4)
Isoproterenol	Approved (phase 4)
Isosorbide Dinitrate	Approved (phase 4)
Isosorbide Mononitrate	Approved (phase 4)
Isradipine	Approved (phase 4)
Ivabradine	Approved (phase 4)
Labetalol	Approved (phase 4)
Lacidipine	Approved (phase 4)
Lercanidipine	Approved (phase 4)
Levamlodipine	Approved (phase 4)
Losartan	Approved (phase 4)
Lovastatin	Approved (phase 4)
Mavacamten	Approved (phase 4)
Mefruside	Approved (phase 4)
Mephentermine	Approved (phase 4)
Mersalyl	Approved (phase 4)
Metaraminol	Approved (phase 4)
Methoxamine	Approved (phase 4)
Methyclothiazide	Approved (phase 4)
Metolazone	Approved (phase 4)
Metoprolol	Approved (phase 4)
Mibefradil	Approved (phase 4)
Midodrine	Approved (phase 4)
Milrinone	Approved (phase 4)
Mipomersen	Approved (phase 4)
Moexipril	Approved (phase 4)
Molsidomine	Approved (phase 4)
Moxisylyte	Approved (phase 4)
Muzolimine	Approved (phase 4)
Nadolol	Approved (phase 4)
Naftazone	Approved (phase 4)
Nebivolol	Approved (phase 4)
Nesiritide	Approved (phase 4)
Niacin	Approved (phase 4)
Nicardipine	Approved (phase 4)
Nicergoline	Approved (phase 4)
Nicorandil	Approved (phase 4)
Nifedipine	Approved (phase 4)
Nimodipine	Approved (phase 4)
Nisoldipine	Approved (phase 4)
Nitrendipine	Approved (phase 4)
Nitroglycerin	Approved (phase 4)
Norepinephrine	Approved (phase 4)
OMEGA-3-ACID ETHYL ESTERS	Approved (phase 4)
Olmesartan Medoxomil	Approved (phase 4)
Oxprenolol	Approved (phase 4)
Pemafibrate	Approved (phase 4)
Penbutolol	Approved (phase 4)
Pentaerythritol Tetranitrate	Approved (phase 4)
Pentoxifylline	Approved (phase 4)
Perhexiline	Approved (phase 4)
Perindopril	Approved (phase 4)
Phenoxybenzamine	Approved (phase 4)
Phentolamine	Approved (phase 4)
Phenylephrine	Approved (phase 4)
Pindolol	Approved (phase 4)
Piretanide	Approved (phase 4)
Pitavastatin	Approved (phase 4)
Policosanol	Approved (phase 4)
Polythiazide	Approved (phase 4)
Practolol	Approved (phase 4)
Pravastatin	Approved (phase 4)
Prenylamine	Approved (phase 4)
Probucol	Approved (phase 4)
Propranolol	Approved (phase 4)
Quinapril	Approved (phase 4)
Quinethazone	Approved (phase 4)
Ramipril	Approved (phase 4)
Ranolazine	Approved (phase 4)
Rosuvastatin	Approved (phase 4)
Simvastatin	Approved (phase 4)
Sotalol	Approved (phase 4)
Spirapril	Approved (phase 4)
Spironolactone	Approved (phase 4)
Suloctidil	Approved (phase 4)
Telmisartan	Approved (phase 4)
Tertatolol	Approved (phase 4)
Ticrynafen	Approved (phase 4)
Timolol	Approved (phase 4)
Tolazoline	Approved (phase 4)
Tolvaptan	Approved (phase 4)
Torsemide	Approved (phase 4)
Trandolapril	Approved (phase 4)
Triamterene	Approved (phase 4)
Trichlormethiazide	Approved (phase 4)
Trimetazidine	Approved (phase 4)
Troxerutin	Approved (phase 4)
Valsartan	Approved (phase 4)
Verapamil	Approved (phase 4)
Vericiguat	Approved (phase 4)
Vincamine	Approved (phase 4)
Volanesorsen	Approved (phase 4)
Acadesine	Phase 3 (in late-stage trials)
Acoramidis	Phase 3 (in late-stage trials)
Allopurinol	Phase 3 (in late-stage trials)
Alteplase	Phase 3 (in late-stage trials)
Arginine	Phase 3 (in late-stage trials)
Aspirin	Phase 3 (in late-stage trials)
Azilsartan Medoxomil	Phase 3 (in late-stage trials)
Azithromycin	Phase 3 (in late-stage trials)
Benidipine	Phase 3 (in late-stage trials)
Bivalirudin	Phase 3 (in late-stage trials)
Bococizumab	Phase 3 (in late-stage trials)
Cagrilintide	Phase 3 (in late-stage trials)
Calcium	Phase 3 (in late-stage trials)
Candesartan	Phase 3 (in late-stage trials)
Centhaquine	Phase 3 (in late-stage trials)
Cholecalciferol	Phase 3 (in late-stage trials)
Cilnidipine	Phase 3 (in late-stage trials)
Cilostazol	Phase 3 (in late-stage trials)
Clazosentan	Phase 3 (in late-stage trials)
Clonidine	Phase 3 (in late-stage trials)
Colchicine	Phase 3 (in late-stage trials)
Dalcetrapib	Phase 3 (in late-stage trials)
Delapril	Phase 3 (in late-stage trials)
Digitalis	Phase 3 (in late-stage trials)
Dipyridamole	Phase 3 (in late-stage trials)
Eptifibatide	Phase 3 (in late-stage trials)
Ergocalciferol	Phase 3 (in late-stage trials)
Estrogens, Conjugated	Phase 3 (in late-stage trials)
Etripamil	Phase 3 (in late-stage trials)
Evacetrapib	Phase 3 (in late-stage trials)
Fasudil	Phase 3 (in late-stage trials)
Febuxostat	Phase 3 (in late-stage trials)
Fimasartan	Phase 3 (in late-stage trials)
Fish Oil	Phase 3 (in late-stage trials)
Fosfocreatine	Phase 3 (in late-stage trials)
Heparin	Phase 3 (in late-stage trials)
Icosapent	Phase 3 (in late-stage trials)
Icosapent Ethyl	Phase 3 (in late-stage trials)
Inclisiran	Phase 3 (in late-stage trials)
Landiolol	Phase 3 (in late-stage trials)
Lerodalcibep	Phase 3 (in late-stage trials)
Levosimendan	Phase 3 (in late-stage trials)
Lisinopril Anhydrous	Phase 3 (in late-stage trials)
Lomitapide	Phase 3 (in late-stage trials)
MANIDIPINE 6300	Phase 3 (in late-stage trials)
Medroxyprogesterone Acetate	Phase 3 (in late-stage trials)
Methotrexate	Phase 3 (in late-stage trials)
Mycophenolate Mofetil	Phase 3 (in late-stage trials)
Nilvadipine	Phase 3 (in late-stage trials)
Olpasiran	Phase 3 (in late-stage trials)
Omecamtiv Mecarbil	Phase 3 (in late-stage trials)
Phytonadione	Phase 3 (in late-stage trials)
Progesterone	Phase 3 (in late-stage trials)
Propatyl Nitrate	Phase 3 (in late-stage trials)
Rauwolfia Serpentina	Phase 3 (in late-stage trials)
Reserpine	Phase 3 (in late-stage trials)
Rimonabant	Phase 3 (in late-stage trials)
Rosiglitazone	Phase 3 (in late-stage trials)
Salicylic Acid	Phase 3 (in late-stage trials)
Semaglutide	Phase 3 (in late-stage trials)
Serelaxin	Phase 3 (in late-stage trials)
Somatropin	Phase 3 (in late-stage trials)
Theobromine	Phase 3 (in late-stage trials)
Ubidecarenone	Phase 3 (in late-stage trials)
Warfarin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Blood Cells, Red, Capsaicin, Clopidogrel, Creatinolfosfate, Dextrin, Doconexent, Doxazosin, Hydralazine, Pelacarsen, Pioglitazone, Prasugrel, Rutin, Sodium Chloride, Vitamin E.

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 17

Druggability breadth: 5 of 19 evidence-associated genes (26%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
GLUL	PREDNISOLONE
BACE1	CIANIDANOL

Top cohort targets by molecule count

Symbol	Molecules	Max phase
BACE1	26	4
GLUL	1	4
SORL1	0	0
STX16	0	0
MEPE	0	0
PRDM16	0	0
AGAP1	0	0
APOA5	0	0
ZNF648	0	0
HHAT	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PREDNISOLONE	4	GLUL
CIANIDANOL	4	BACE1
DONEPEZIL	4	BACE1
CHLOROQUINE	4	BACE1
GEFITINIB	4	BACE1
TYRAMINE	3	BACE1
CURCUMIN	3	BACE1
CAFFEIC ACID	3	BACE1
HYDROXYTYROSOL	3	BACE1
RUTIN	3	BACE1
EPIGALOCATECHIN GALLATE	3	BACE1
VERUBECESTAT	3	BACE1
LANABECESTAT	3	BACE1
ELENBECESTAT	3	BACE1
PHLOROGLUCINOL	3	BACE1
QUERCETIN	3	BACE1
(+)-EPICATECHIN	2	BACE1
SPICLOMAZINE	2	BACE1
LUTEOLIN	2	BACE1
ATABECESTAT	2	BACE1
ACETOSIDE	2	BACE1
(-)-EPICATECHIN	2	BACE1
ELLAGIC ACID	2	BACE1
KAEMPFEROL	1	BACE1
AZD-3839	1	BACE1
LY-2811376	1	BACE1
LY-2886721	1	BACE1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 4.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
BACE1	1,237	Binding:1230, Functional:6, ADMET:1
GLUL	45	Binding:45
HHAT	14	Binding:14
PRDM16	2	Binding:2
GK	2	Binding:2

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
PRDM16	2.1.1.367, 2.1.1.370	[histone H3]-lysine9 N-methyltransferase, [histone H3]-lysine4 N-dimethyltransferase
GK	2.7.1.30	glycerol kinase
GLUL	6.3.1.2	glutamine synthetase
BACE1	3.4.23.46	memapsin 2

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
BACE1	1,237

Pharmacogenomics

Cohort genes with a PharmGKB record: 19; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

27 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
PREDNISOLONE	4	GLUL
CIANIDANOL	4	BACE1
DONEPEZIL	4	BACE1
CHLOROQUINE	4	BACE1
GEFITINIB	4	BACE1
TYRAMINE	3	BACE1
CURCUMIN	3	BACE1
CAFFEIC ACID	3	BACE1
HYDROXYTYROSOL	3	BACE1
RUTIN	3	BACE1
EPIGALOCATECHIN GALLATE	3	BACE1
VERUBECESTAT	3	BACE1
LANABECESTAT	3	BACE1
ELENBECESTAT	3	BACE1
PHLOROGLUCINOL	3	BACE1
QUERCETIN	3	BACE1
(+)-EPICATECHIN	2	BACE1
SPICLOMAZINE	2	BACE1
LUTEOLIN	2	BACE1
ATABECESTAT	2	BACE1
ACETOSIDE	2	BACE1
(-)-EPICATECHIN	2	BACE1
ELLAGIC ACID	2	BACE1
KAEMPFEROL	1	BACE1
AZD-3839	1	BACE1
LY-2811376	1	BACE1
LY-2886721	1	BACE1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	GLUL, BACE1
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	4	SORL1, FLNC, CADM1, IL1RAPL1
D	Druggable family + AlphaFold only, no drug	1	GK
E	Difficult family or no structure, no drug	12	STX16, MEPE, PRDM16, AGAP1, APOA5, ZNF648, HHAT, SAYSD1, APCDD1L, BUD13 (+2 more)

Undrugged target profiles

17 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
SORL1	0	—
STX16	0	—
MEPE	0	—
PRDM16	2	—
AGAP1	0	—
APOA5	0	—
ZNF648	0	—
HHAT	14	—
SAYSD1	0	—
APCDD1L	0	—
BUD13	0	—
BLID	0	—
FLNC	0	—
GK	2	—
CADM1	0	—
IL1RAPL1	0	—
IRX4	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 4,079.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	270
PHASE3	254
PHASE4	220
PHASE2	165
PHASE1	118
PHASE1/PHASE2	27
PHASE2/PHASE3	25
EARLY_PHASE1	21

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03520660	PHASE4	ACTIVE_NOT_RECRUITING	People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
NCT04262206	PHASE4	RECRUITING	Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
NCT04263038	PHASE4	RECRUITING	Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
NCT04286399	PHASE4	RECRUITING	Asian Diabetes Outcomes Prevention Trial
NCT04715568	PHASE4	RECRUITING	Secondhand Tobacco Smoke and Cardiovascular Disease
NCT05242315	PHASE4	RECRUITING	Extended-Release Tacrolimus Following Liver Transplantation
NCT05284747	PHASE4	ACTIVE_NOT_RECRUITING	EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
NCT05361421	PHASE4	ACTIVE_NOT_RECRUITING	Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD Trial
NCT05498376	PHASE4	ACTIVE_NOT_RECRUITING	The Leadless AV Versus DDD Pacing Study
NCT05700877	PHASE4	RECRUITING	Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes
NCT05932472	PHASE4	RECRUITING	Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial
NCT05995600	PHASE4	RECRUITING	Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
NCT06263452	PHASE4	RECRUITING	Beta-Blocker Influences on Inflammatory and Neural Responses to Stress
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial
NCT06336317	PHASE4	RECRUITING	Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE
NCT06625073	PHASE4	RECRUITING	Randomized Trial of SGLT2i in Heart Transplant Recipients
NCT06642623	PHASE4	RECRUITING	A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients
NCT06676280	PHASE4	RECRUITING	ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography
NCT06873321	PHASE4	RECRUITING	VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
NCT06959784	PHASE4	ENROLLING_BY_INVITATION	Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
NCT07026539	PHASE4	RECRUITING	Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.
NCT07370688	PHASE4	RECRUITING	Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation
NCT07482943	PHASE4	NOT_YET_RECRUITING	The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure
NCT07483801	PHASE4	NOT_YET_RECRUITING	DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
NCT07485283	PHASE4	RECRUITING	Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
NCT07507409	PHASE4	NOT_YET_RECRUITING	Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients
NCT00000521	PHASE4	COMPLETED	Sodium-Potassium Blood Pressure Trial in Children
NCT00025766	PHASE4	COMPLETED	Angioplasty and Heart Stents to Treat Individuals With an Occluded Artery Following a Heart Attack
NCT00083772	PHASE4	TERMINATED	Use of Nesiritide in the Management of Acute Diastolic Heart Failure
NCT00106886	PHASE4	UNKNOWN	HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)
NCT00123045	PHASE4	COMPLETED	Patient-Physician Partnership to Improve High Blood Pressure Adherence
NCT00127348	PHASE4	COMPLETED	Effect of Continuous Positive Airway Pressure (CPAP) on Hypertension and Cardiovascular Morbidity-Mortality in Patients With Sleep Apnea and no Daytime Sleepiness
NCT00134160	PHASE4	COMPLETED	OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study
NCT00135551	PHASE4	COMPLETED	Benidipine-based Comparison of Angiotensin Receptors, β-blockers, or Thiazide Diuretics in Hypertensive Patients
NCT00147251	PHASE4	COMPLETED	Stop Atherosclerosis in Native Diabetics Study
NCT00147602	PHASE4	COMPLETED	Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke
NCT00153101	PHASE4	COMPLETED	Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
NCT00159835	PHASE4	COMPLETED	Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD
NCT00169910	PHASE4	COMPLETED	VIP: Vascular Imaging Project. Study on the Progression of Cardiovascular Disease in Renal Transplant Recipients
NCT00181818	PHASE4	COMPLETED	Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ENALAPRIL	4	18
ROSUVASTATIN	4	14
CLOPIDOGREL	4	13
AMIODARONE	4	12
METOPROLOL	4	10
BISOPROLOL	4	9
PROPRANOLOL	4	9
SIMVASTATIN	4	9
ATORVASTATIN	4	8
NIACIN	4	8
CHLORTHALIDONE	4	7
PRAVASTATIN	4	7
VITAMIN E	4	7
LISINOPRIL ANHYDROUS	4	6
WARFARIN	4	6
ALLOPURINOL	4	5
DIPYRIDAMOLE	4	5
LOVASTATIN	4	5
PRASUGREL	4	5
ASPIRIN	4	4
CHOLESTYRAMINE	4	4
EMPAGLIFLOZIN	4	4
ESTRADIOL	4	4
MEDROXYPROGESTERONE ACETATE	4	4
SOTALOL	4	4
TICAGRELOR	4	4
ADALIMUMAB	4	3
ALCOHOL	4	3
ASCORBIC ACID	4	3
ATENOLOL	4	3

Cohort genes: SORL1, STX16, MEPE, PRDM16, AGAP1, APOA5, ZNF648, HHAT, SAYSD1, APCDD1L, BUD13, BLID, FLNC, GK, GLUL, CADM1, IL1RAPL1, IRX4, BACE1
Drugs: Enalapril, Rosuvastatin, Clopidogrel, Amiodarone, Metoprolol, Bisoprolol, Propranolol, Simvastatin, Atorvastatin, Niacin, Chlorthalidone, Pravastatin, Vitamin E, Lisinopril, Warfarin, Allopurinol, Dipyridamole, Lovastatin, Prasugrel, Aspirin, Cholestyramine, Empagliflozin, Estradiol, Medroxyprogesterone Acetate, Sotalol, Ticagrelor, Adalimumab, Alcohol, Ascorbic Acid, Atenolol